Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer
Apatinib, an anti-tumor drug selectively targeting VEGFR2 (Vascular Endothelia Growth Factor Recpetor-2), has been proven effective in Chinese patients with liver cancer. Generally, treatment with apatinib achieves 16.1% of the overall objective remission rate (ORR) and 55.83% of the disease control...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.624369/full |
id |
doaj-b43d4ed7cfe042b791a97e64231eb565 |
---|---|
record_format |
Article |
spelling |
doaj-b43d4ed7cfe042b791a97e64231eb5652021-04-26T07:06:42ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-04-011110.3389/fonc.2021.624369624369Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver CancerHui Xia0Cheng Zhou1Zhaoxia Luo2Ping Zhang3Liping Zhu4Zhao Gong5Department of Hepatobiliary Surgery, Wuhan No. 1 Hospital, Wuhan, ChinaDepartment of Hepatobiliary Surgery, Wuhan No. 1 Hospital, Wuhan, ChinaDepartment of Hepatobiliary Surgery, Wuhan No. 1 Hospital, Wuhan, ChinaDepartment of Dermatology, Wuhan No. 1 Hospital, Wuhan, ChinaDepartment of Hepatobiliary Surgery, Wuhan No. 1 Hospital, Wuhan, ChinaDepartment of Hepatobiliary Surgery, Wuhan No. 1 Hospital, Wuhan, ChinaApatinib, an anti-tumor drug selectively targeting VEGFR2 (Vascular Endothelia Growth Factor Recpetor-2), has been proven effective in Chinese patients with liver cancer. Generally, treatment with apatinib achieves 16.1% of the overall objective remission rate (ORR) and 55.83% of the disease control rate (DCR) in Chinese patients with liver cancer. However, the prevalence of apatinib-induced hand–foot skin reaction (AI-HFSR) is noticeably high. The incidence of AI-HFSR is about 50.5%, of which Grades 1/2 and 3 are 38.8 and 11.6%, respectively. In addition, potential molecular mechanisms underlying the development of AI-HFSR are poorly understood and urgently needed to be investigated histologically. In this review, we summarize and review the current efficacy of apatinib and the prevalence of AI-HFSR in Chinese patients with liver cancer. Besides, we postulate the potential mechanisms underlying the development of AI-HFSR and discuss the optimal clinical management for this unwanted cutaneous side effect.https://www.frontiersin.org/articles/10.3389/fonc.2021.624369/fullapatinibhand–foot skin reactionmechanismsmanagementChinese |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hui Xia Cheng Zhou Zhaoxia Luo Ping Zhang Liping Zhu Zhao Gong |
spellingShingle |
Hui Xia Cheng Zhou Zhaoxia Luo Ping Zhang Liping Zhu Zhao Gong Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer Frontiers in Oncology apatinib hand–foot skin reaction mechanisms management Chinese |
author_facet |
Hui Xia Cheng Zhou Zhaoxia Luo Ping Zhang Liping Zhu Zhao Gong |
author_sort |
Hui Xia |
title |
Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer |
title_short |
Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer |
title_full |
Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer |
title_fullStr |
Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer |
title_full_unstemmed |
Apatinib-Induced Hand–Foot Skin Reaction in Chinese Patients With Liver Cancer |
title_sort |
apatinib-induced hand–foot skin reaction in chinese patients with liver cancer |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-04-01 |
description |
Apatinib, an anti-tumor drug selectively targeting VEGFR2 (Vascular Endothelia Growth Factor Recpetor-2), has been proven effective in Chinese patients with liver cancer. Generally, treatment with apatinib achieves 16.1% of the overall objective remission rate (ORR) and 55.83% of the disease control rate (DCR) in Chinese patients with liver cancer. However, the prevalence of apatinib-induced hand–foot skin reaction (AI-HFSR) is noticeably high. The incidence of AI-HFSR is about 50.5%, of which Grades 1/2 and 3 are 38.8 and 11.6%, respectively. In addition, potential molecular mechanisms underlying the development of AI-HFSR are poorly understood and urgently needed to be investigated histologically. In this review, we summarize and review the current efficacy of apatinib and the prevalence of AI-HFSR in Chinese patients with liver cancer. Besides, we postulate the potential mechanisms underlying the development of AI-HFSR and discuss the optimal clinical management for this unwanted cutaneous side effect. |
topic |
apatinib hand–foot skin reaction mechanisms management Chinese |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.624369/full |
work_keys_str_mv |
AT huixia apatinibinducedhandfootskinreactioninchinesepatientswithlivercancer AT chengzhou apatinibinducedhandfootskinreactioninchinesepatientswithlivercancer AT zhaoxialuo apatinibinducedhandfootskinreactioninchinesepatientswithlivercancer AT pingzhang apatinibinducedhandfootskinreactioninchinesepatientswithlivercancer AT lipingzhu apatinibinducedhandfootskinreactioninchinesepatientswithlivercancer AT zhaogong apatinibinducedhandfootskinreactioninchinesepatientswithlivercancer |
_version_ |
1721507725604552704 |